Cardiovascular Devices Market Size, Share, Growth and Forecast, 2025-2035

Cardiovascular devices market grows on catheter therapies

The global cardiovascular devices market was valued at USD 68.73 billion in 2025 and is projected to increase from USD 73.35 billion in 2026 to USD 131.73 billion by 2035, registering a CAGR of 6.72% during 2026–2035. Demand comes from aging populations, rising rates of coronary artery disease, atrial fibrillation and heart failure, and a steady shift from open surgery toward catheter-based treatment. North America held the largest regional share, 40.0% in 2025, because high procedure volumes and broad reimbursement support premium implants and ablation systems. Asia Pacific is the fastest-growing region at 7.87% a year, as China, India and Southeast Asia add catheterization laboratories and wider insurance coverage. The technology picture shifted in 2024 and 2025, when U.S. regulators approved several pulsed field ablation systems for atrial fibrillation. As a result, electrophysiology has become the most dynamic product area, while imaging and monitoring keep a large installed base.

Which products and care settings does this analysis cover?

The analysis counts cardiac imaging systems, rhythm management implants, cardiac assist devices, interventional cardiology products, electrophysiology systems and cardiac monitoring equipment, valued at manufacturer selling prices. Hospitals buy most capital equipment and implants through group purchasing contracts, while clinics, ambulatory surgical centers and home care providers buy monitors and lower-acuity procedure kits.

Heart medicines, standalone laboratory tests and software sold without hardware sit outside the scope of this analysis. The value chain runs from component and sensor suppliers through device makers to distributors, hospital purchasing groups and the cardiologists and surgeons who select products for each procedure.

Interventional cardiology leads as ablation gains pace

Why does interventional cardiology still lead product spending?

Based on product, the market is categorized into cardiac imaging, rhythm management, cardiac assist devices, interventional cardiology, electrophysiology and monitoring. Interventional Cardiology led with a 30.0% share of 2025 value, because coronary stents, balloons, guidewires and catheters are used in high volumes in every catheterization laboratory. Electrophysiology grows fastest at 9.46% a year, as pulsed field ablation systems widen treatment for atrial fibrillation. Rhythm management keeps a large base of implants that need periodic battery replacement.

Which care settings buy most cardiac technology?

Based on end user, the market is categorized into hospitals, home care settings, ambulatory surgical centers, research institutes and clinics. The Hospital segment led with a 62.0% share of 2025 value, because hospitals house the catheterization laboratories, hybrid operating rooms and intensive care units that complex procedures require. The Home Care Setting segment grows fastest at 8.42% a year, as wearable monitors and remote follow-up of implants move routine care into the home. Ambulatory surgical centers also gain volume as payers accept more outpatient cardiac procedures.

Heart disease burden and aging patients lift procedures

How does the global burden of heart disease sustain demand?

Cardiovascular disease creates the core demand, because heart attacks, strokes, arrhythmias and valve disease all require diagnosis and often a device-based treatment. The World Health Organization estimates that 19.8 million people died from cardiovascular diseases in 2022, about 32% of all global deaths. Heart attack and stroke caused 85% of these deaths, and many survivors later need stents, monitors or implants. As a result, procedure volumes rise steadily with population growth and longer survival after a first cardiac event.

Why do aging patients widen the structural heart pool?

Aging populations widen the pool of structural heart patients, because aortic stenosis and leaky heart valves become far more common in later life. In May 2025, Edwards Lifesciences announced FDA approval of its SAPIEN 3 platform for severe aortic stenosis patients without symptoms, the first such approval for transcatheter aortic valve replacement. The decision rests on trial data showing better outcomes than watchful waiting. In turn, valve programs can treat patients earlier, which lifts implant volumes in North America first.

Download Free Sample

How is earlier atrial fibrillation treatment lifting ablation volumes?

Rising treatment of atrial fibrillation drives electrophysiology spending, because catheter ablation is now offered earlier instead of after years of drug therapy. In January 2024, Boston Scientific announced FDA approval of its FARAPULSE system, a pulsed field ablation platform that isolates the pulmonary veins with electrical pulses rather than heat or cold. Shorter procedures let electrophysiology laboratories treat more patients each day. As a result, hospitals are adding mapping systems, catheters and laboratory capacity across the United States and Europe.

Why does chronic disease monitoring add recurring demand?

Chronic disease monitoring adds recurring demand, because large populations with hypertension, heart failure and arrhythmia need regular tracking outside hospitals. The World Health Organization reported in September 2025 that 1.4 billion people lived with hypertension in 2024, and just over one in five had it under control. Wearable patches, implantable loop recorders and remote patient monitoring platforms help clinicians detect problems before patients need emergency care. In turn, home care settings become a growing buyer of cardiac monitoring equipment.

Pulsed field ablation and valve repair reshape demand

How is pulsed field ablation shifting electrophysiology?

Pulsed field ablation is replacing thermal energy as the preferred approach in many laboratories, because it targets heart tissue while sparing nearby structures. In October 2024, Medtronic announced FDA approval of its Affera mapping and ablation system with the Sphere-9 catheter, which combines high-density mapping with pulsed field and radiofrequency energy. Abbott followed in December 2025, when it announced that U.S. regulators had approved its Volt pulsed field ablation system for atrial fibrillation. As a result, competition now centers on catheter design and mapping integration.

Why is transcatheter repair rising beyond the aortic valve?

Catheter-based repair is spreading to the mitral and tricuspid valves, because many older patients are too frail for open-heart surgery. In April 2024, Abbott announced FDA approval of TriClip, a first-of-its-kind transcatheter edge-to-edge repair system for a leaky tricuspid valve. Structural heart programs that already perform aortic valve replacement can add these procedures with existing imaging and catheter skills. In turn, hospitals spend more on imaging guidance, delivery systems and dedicated heart team staff.

Download Free Sample

Can new imaging agents open a cardiac PET opportunity?

Cardiac imaging vendors have a clear opening in positron emission tomography, because PET perfusion scans can deliver higher diagnostic accuracy than the SPECT scans still used in most nuclear cardiology. In September 2024, GE HealthCare announced FDA approval of Flyrcado, a fluorine-18 radiotracer for diagnosing coronary artery disease. Its half-life is more than 10 times longer than other approved cardiac PET tracers, which makes exercise stress testing with PET practical. As a result, more hospitals and imaging centers could justify PET scanners for cardiology.

Where can device makers win share in emerging markets?

Device makers have room to grow in Asia, Latin America and the Middle East, where many hospitals are still opening their first catheterization laboratories. Patients in these regions often reach treatment late, so new laboratories quickly fill with coronary and rhythm cases. Companies that pair affordable products with physician training and service networks can build loyalty early. As a result, mid-priced platforms and refurbished imaging systems have strong prospects in these regions over the next decade.

Pricing, safety rules and staffing gaps slow uptake

Why does hospital price pressure limit value growth?

Price pressure is the main commercial constraint, because hospitals buy stents, catheters and implants through large tenders and group purchasing contracts. Volume-based procurement in China has cut prices for coronary stents and other high-use products, and similar tender models exist across Europe. Suppliers must therefore lower prices while keeping quality and service standards high. As a result, unit volumes can rise faster than market value, especially for mature products with many competing makers.

How do safety rules and recalls slow product launches?

Strict safety rules slow product launches, because implantable heart products carry high clinical risk and require extensive trial data. Approval of a new valve, ablation catheter or assist pump can take several years, and post-market surveillance continues after launch. Recalls of implants or leads can damage physician trust and lead hospitals to switch suppliers. In turn, smaller companies often need partners with large clinical and regulatory teams to bring new technologies to market.

Why do staffing gaps cap procedure capacity?

Shortages of trained staff limit how many procedures hospitals can perform, because electrophysiology and structural heart cases need specialized physicians, nurses and imaging technicians. Many regions outside large cities lack cardiologists who can perform catheter ablation or valve replacement. Training programs take years to expand, even when hospitals can afford new equipment. As a result, installed systems in some emerging markets run below capacity, which slows repeat purchases of catheters and implants.

How do capital costs and reimbursement gaps slow adoption?

High capital costs slow adoption of imaging systems, mapping platforms and hybrid operating rooms, because each installation requires a major hospital budget. Reimbursement for newer procedures often lags behind clinical evidence, which delays uptake in public health systems. Patients in low- and middle-income countries frequently pay out of pocket for implants such as pacemakers and heart valves. In turn, many eligible patients go untreated, and suppliers must offer financing or leasing models to win contracts.

North America leads as Asia Pacific builds cath labs

Why does North America hold the largest regional share?

North America held a 40.0% share of 2025 value and grows at 6.27% a year through 2035. The United States drives this position, because hospitals there perform large volumes of ablation, valve replacement and coronary procedures. U.S. health spending reached 16.7% of gross domestic product in 2023, according to World Bank data, the highest among major economies, and 17.9% of U.S. residents were 65 or older in 2024. Regulators approved several new ablation and valve products between 2024 and 2025, which keeps premium technologies reaching this region first.

How fast is Asia Pacific adding cardiac capacity?

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 7.87% a year. China, India and Southeast Asia are expanding catheterization laboratory capacity, which brings procedural treatment to patients who previously received medicines alone. Japan contributes high-value demand from an aging population, where people aged 65 and older made up 29.8% of residents in 2024 and health spending reached 10.7% of GDP in 2023. China spent 5.9% of GDP on health in 2023 and India 3.3%, which leaves wide room for investment in cardiac care. Local manufacturers in China and India compete strongly on stents and basic monitoring equipment.

Download Free Sample

What shapes demand across Europe?

Europe held a 26.0% share of 2025 value and grows at 6.07% a year, the slowest pace of the five regions. Germany, France, the United Kingdom and Italy account for most spending, and health spending equaled 11.7% of GDP in Germany, 11.5% in France and 11.0% in the United Kingdom in 2023. Tender-based purchasing and stricter rules under the European Medical Device Regulation hold back price growth and launch speed. However, aging populations keep demand for valves, implants and ablation steady, since people aged 65 and older made up 24.6% of Italy's population and 23.2% of Germany's in 2024.

Where is Latin America adding demand?

Latin America held a 6.0% share of 2025 value and grows at 7.17% a year through 2035. Brazil and Mexico lead regional demand, and Brazil spent 9.7% of GDP on health in 2023, with private hospitals investing in catheterization laboratories and imaging systems. Public health systems buy stents and implants through tenders, which keeps prices low but supports steady volume.

What limits growth in the Middle East and Africa?

The Middle East and Africa held a 4.0% share of 2025 value and grows at 7.37% a year through 2035. Gulf states add higher-value demand from new cardiac centers that buy advanced imaging and structural heart products. Access in sub-Saharan Africa remains limited, because many countries have few catheterization laboratories outside major cities.

Download Free Sample

FDA approvals in ablation and valve therapy since 2024

Energy sources, imaging agents and sensors lead innovation

• Pulsed field ablation uses short electrical pulses to isolate heart tissue, which reduces the risk of heat damage to nearby structures such as the esophagus.
• Transcatheter repair and replacement systems deliver valves and clips through blood vessels, which lets frail patients avoid open-heart surgery.
• Cardiac PET radiotracers such as flurpiridaz F 18 allow perfusion imaging with exercise stress, which supports diagnosis of coronary artery disease.
• Wearable and implantable monitors send heart rhythm data to clinicians remotely, which supports earlier detection of arrhythmias and implant problems.

Diversified medtech leaders compete on full cardiac suites

Competition is led by diversified medical technology companies that sell across several cardiac product areas, from ablation catheters to valves and implants. Medtronic, Abbott and Boston Scientific Corporation compete directly in electrophysiology, where each now markets a pulsed field ablation system in the United States. Edwards Lifesciences Corporation focuses on transcatheter heart valves and structural heart repair, while W.L. Gore & Associates supplies vascular grafts, stent grafts and septal occluders used in cardiac and vascular procedures. GE HealthCare, Siemens Healthcare GmbH and Canon Medical Systems compete in cardiac imaging, including ultrasound, computed tomography and angiography systems. BIOTRONIK SE & Co. KG specializes in pacemakers, defibrillators and remote monitoring, and LivaNova PLC supplies cardiopulmonary equipment for heart surgery, while Cardinal Health and B. Braun SE add catheters, drug-coated balloons, consumables and hospital distribution services across many countries. As a result, buyers often favor suppliers that offer complete laboratory suites, training and service under a single contract.

Companies profiled and their roles in this market

Electrophysiology and structural heart set the growth pace

Credence Research's view is that electrophysiology and structural heart products will set the pace of growth through 2035, because both replace drug therapy or open surgery with shorter catheter procedures. The overall market grows at 6.72% a year, supported by aging populations and higher procedure capacity in Asia Pacific. Imaging and monitoring keep large installed bases, but price pressure limits their value growth. Companies that combine strong clinical data with training, service and financing will win the most new laboratories, while single-product suppliers face pressure from bundled contracts.

How Credence Research sized cardiac device spending

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, which builds spending by product, end user and region. Regional and segment splits are Credence Research estimates informed by World Health Organization and World Bank statistics, U.S. regulator decisions and company press releases. No primary interviews or surveys were used in preparing this edition of the report.

Cardiac device spending outlook to 2035

By 2035, the cardiovascular devices market is projected to reach USD 131.73 billion, with growth led by electrophysiology, structural heart programs and home monitoring. Interventional cardiology will remain the largest product area, although price pressure will keep its value growth moderate. North America keeps the highest spending per patient, while Asia Pacific adds the most new laboratories and implant users. Outpatient and home settings will take a larger share of routine procedures and follow-up care. As a result, advantage will depend on clinical evidence, laboratory integration and service reach.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.